5 citations
,
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” This study reports on an ongoing Phase I/IIa clinical trial of ex vivo gene therapy for treating severe Recessive Dystrophic Epidermolysis Bullosa, involving six adult participants with COL7A1 mutations resulting in deficient type VII collagen production.
101 citations
,
December 2010 in “The journal of investigative dermatology/Journal of investigative dermatology” This study reports the successful differentiation of mouse induced pluripotent stem cells into keratinocytes that can regenerate skin and its structures in an in vivo environment.
22 citations
,
March 2023 in “Bioengineering” This review discusses stem cell therapy as a promising treatment for epidermolysis bullosa, highlighting preliminary successes in treating skin lesions but noting the need for further research on effectiveness and safety.
25 citations
,
August 2007 in “Molecular Therapy” This study found that using ectopic expression of CD24 is a promising approach for selecting genetically modified human epidermal stem cells for safe cutaneous gene therapy in cancer-prone conditions.
September 2013 in “Experimental Dermatology” The document concluded that stem cells are crucial for skin repair, regeneration, and may help in developing advanced skin substitutes.